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mass spectrometry; Fmoc – fluorenylmethoxycarbonyl; Gly - glycine; IL – intraligand; Lys – lysine; 
Maldi-tof – Matrix assisted laser/desorption ionization - time of flight; MLCT - Metal to Ligand 
Charge Transfer; PNA – peptide nucleic acid; SPPS – solid phase peptide synthesis; TFA – 
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Abstract. 
A new rhenium tricarbonyl complex of a bis(quinoline)-derived ligand (2-azido-N,N-bis((quinolin-2-
yl)methyl)ethanamine, L-N3), namely [Re(CO)3(L-N3)]Br was synthesized and characterized in-depth, 
including by X-ray crystallography. [Re(CO)3(L-N3)]Br exhibits a strong UV absorbance in the range 
300-400 nm with a maximum at 322 nm, and upon photoexcitation, shows two distinct emission bands 
at about 430 and 560 nm in various solvents (water, ethylene glycol). [Re(CO)3(L-N3)]Br could be 
conjugated, on the solid phase, to a peptide nucleic acid (PNA) oligomer using the copper(I)-catalyzed 
azide-alkyne cycloaddition reaction (Cu-AAC, “click” chemistry) and an alkyne-containing PNA 
building block to give Re-PNA. It was demonstrated that upon hybridisation with a complementary 
DNA strand (DNA), the position of the maxima and emission intensity for the hybrid Re-PNA•DNA 
remained mainly unchanged compared to those of the single strand Re-PNA. The rhenium-containing 
PNA oligomer Re-PNA could be then mediated in living cells where they have been shown to be non-
toxic contrary to the general notion that organometallic compounds are usually unstable under 
physiological conditions and/or cytotoxic. Furthermore, Re-PNA could be detected in living cells 
using fluorescent microscopy. 
 4
Introduction 
Peptide Nucleic Acids (PNAs) are non-natural nucleic acid analogues.1, 2  The usual phosphate-ribose 
backbone of DNA/RNA is replaced in PNA by a neutral pseudo-peptide backbone made of N-(2-
aminoethyl)glycine units, which are ligated, via a methylene carbonyl group, to one of the four 
nucleobases.1 PNAs possess attractive properties, which include good chemical stability, resistance to 
nucleases and proteases, high binding affinity for DNA/RNA strands, great discrimination of single-
base mismatches, and fast hybridization kinetics. These favorable characteristics have led to the 
investigation of PNAs, for example, as agents in antisense3-5 and antigene therapy.6-8 
The covalent attachment of metal complexes to PNA oligomers is currently being intensively 
investigated all around the world.9 These metal conjugates have found applications in various research 
fields such as radioactive probes, as in the sequence-specific detection of nucleic acids, in the 
hydrolysis of nucleic acids and peptides, or as modulators of PNA•DNA hybrid stability.9 However, to 
the best of our knowledge, there has been no report, to date, of the utilization of metal-PNAs for gene 
silencing. This is rather surprising as the addition of a specific metal complex to a PNA oligomer can 
be of significant interest. Our group10 and Krämer et al.11 have, for example, demonstrated that simply 
attaching a metal complex to PNA bioconjugates can significantly increase the cellular uptake of PNA. 
Recently, Licandro and co-workers have reported the preparation and photophysical properties of 
luminescent dinuclear rhenium(I) tricarbonyl complex-PNA conjugates.12 One of their Re-PNA 
conjugates showed interesting two-photon absorption properties, which was exploited for imaging 
experiments in HEK-293 cells.12  
In the present study, a fluorescent metal complex was covalently linked to a PNA oligomer. We were 
curious to investigate to which extend the presence of a metal complex would affect the intrinsic 
biological properties of the resulting bioconjugate. As a note of caution, Barton et al. have studied the 
mechanism of cellular uptake of a series of ruthenium complexes and Ru-peptide bioconjugates.13-17 
They demonstrated how the addition of an organic fluorophore to inorganic fluorophore-tagged cell-
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penetrating peptide (CPP) bioconjugates induced a change in transport pathway as well as in 
subcellular distribution of the new bioconjugate.15 These discoveries further emphasize the interest of 
employing metallo-fluorophores. Indeed, contrary to a “normal” organic fluorophore, the presence of a 
metal complex not only allows lifetime imaging but can also lead to further opportunities such as the 
use of Atomic Absorption Spectroscopy (AAS) to quantify the uptake of the conjugates.5 
Herein, we present the preparation and in-depth characterization, including X-ray crystallography, of 
a novel rhenium tricarbonyl complex ([Re(CO)3(L-N3)]Br, Figure 1) of a bis-quinoline derivative 
ligand, 2-azido-N,N-bis((quinolin-2-yl)methyl)ethanamine (L-N3, Figure 1), which was selected in this 
work as the organometallic moiety of choice. Re tricarbonyl complexes with similar ligands have been 
indeed shown to have favorable optical properties such as large Stokes shift, long lifetime, and 
polarized emission. Due to their good chemical stability and facile preparation, these complexes as well 
as their 99mTc congeners, were already used for the (radio-)labeling of biomolecules by Zubieta, 
Valliant, Babich and our groups for both in vitro and in vivo imaging purposes.18-30 We then report on 
the facile coupling of [Re(CO)3(L-N3)]Br, on the solid-phase, to an alkyne-containing PNA oligomer 
(Re-PNA). The possibility to detect Re-PNA in living cells by fluorescence microscopy is also 
presented. A high binding affinity of this metal-PNA bioconjugate to complementary DNA was 
confirmed by UV melting studies. 
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Figure 1. Structures of Fmoc-1-OH, L-N3 and [Re(CO)3(L-N3)]Br. 
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Results and discussion 
Synthesis and characterization of [Re(CO)3(L-N3)]Br. 2-Azido-N,N-bis((quinolin-2-
yl)methyl)ethanamine (L-N3) was obtained by reacting 2-(bis((quinolin-2-yl)methyl)amino)ethanol (L-
OH)31 with triphenyl phosphine, diisopropyl azodicarboxylate and diphenylphosphoryl azide in THF 
following a similar procedure described by our groups (Scheme 1).32 The presence of L-N3 was 
ascertained by IR spectroscopy with a strong vibration at 2093 cm-1 corresponding to the azide 
function. The Re complex [Re(CO)3(L-N3)]Br could then be obtained in good yield by refluxing 
[NEt4][ReBr3(CO)3]33 with L-N3 in methanol. As expected, [Re(CO)3(L-N3)]Br exhibits a sharp, 
strong band at 2025 cm-1 and a broad and intense absorption at 1897 cm-1, attributed to the (C-O) 
bands of A and E symmetry of the fac-[Re(CO)3] moiety, as well as another strong band at 2101 cm-1 
corresponding to the azide function. In ESI-MS, the base peak at m/z = 639 was assigned to 
[Re(CO)3(L-N3)]+, with the expected isotope fingerprint of 185,187Re observed. The 1H-NMR spectrum 
of [Re(CO)3(L-N3)]Br in CD3OD showed two sets of doublets at about 5.30 ppm, corresponding to the 
four methylene protons adjacent to the quinoline rings (Figure S2 in the SI).19 In comparison, for L-N3, 
only a singlet is observed for these four protons (Figure S1 in the SI). In CD3OD, the four methylene 
protons adjacent to the quinoline rings are rapidly exchanged with deuterium as shown by mass 
spectrometry and NMR spectroscopy (Figures S3–5 in the SI), paralleling similar behavior in other Re 
tricarbonyl complexes that we have recently reported.32 
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Scheme 1. Synthesis of [Re(CO)3(L-N3)]Br. (a) PPh3, diisopropyl azodicarboxylate, 
diphenylphosphoryl azide, THF, 72h, 32% (b) [NEt4]2[Re Br3(CO)3], MeOH, 3h, 84%. 
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X-ray crystallography of [Re(CO)3(L-N3)]Br. Figure 2 shows the molecular structure of the Re 
tricarbonyl complex [Re(CO)3(L-N3)]Br. The coordination number around each Re centre is six in an 
approximate octahedral coordination environment. The Re-C bond distances (1.904(10) to 1.940(10) 
Å) and the nearly linear azido group (N4-N5 1.220(14), N5-N6 1.110(16), N4-N5-N6 173.1(14)) in 
[Re(CO)3(L-N3)]Br are reminiscent of related Re complexes34, 35 and azido compounds.36, 37 
 
Figure 2. ORTEP plot of [Re(CO)3(L-N3)]Br in the asymmetric unit at 50 % probability levels. 
Selected bond distances (Å) and angles (°): Re1-C23 1.936(11), Re1-C24 1.904(10), Re1-C25 
1.940(10), C23-O1 1.127(14), C24-O2 1.143(13), C25-O3 1.126(13), N3-C19 1.478(13), C19-C20 
1.545(14), C20-N4 1.466(16), N4-N5 1.220(14), N5-N6 1.110(16), N3-C19-C20 116.4(8), C19-C20-
N4 108.9(9), C20-N4-N5 114.7(10), N4-N5-N6 173.1(14). 
 
Optical properties of [Re(CO)3(L-N3)]Br. The photophysical data of [Re(CO)3(L-N3)]Br are 
comparable to those previously reported by Zubieta et al. for related bis-quinoline Re tricarbonyl 
complexes.18, 19, 22 [Re(CO)3(L-N3)]Br exhibits a strong UV absorbance in the range 300-400 nm with 
a maximum at 322 nm (see Figure S6 in the SI). These transitions most likely have considerable metal-
to-ligand-charge-transfer (MLCT: d(Re) –> *(ligand)).19 
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Upon photoexcitation, the rhenium complex shows two distinct emission bands at about 430 and 560 
nm in various solvents (e.g. water, ethylene glycol). Ethylene glycol was found to enhance the intensity 
of the band at 560 nm (relative to the one at 430 nm, see Figure 4). The high-energy transition is 
assigned to ligand-centered fluorescence, whilst the lower energy transition originates from a 3MLCT 
state (see Figure 3 for emission spectra of [Re(CO)3(L-N3)]Br and Table 1 for a summary of its 
photophysical data). Luminescence lifetime measurements for the emission at 560 nm (exc = 325 nm) 
were carried out in both degassed and air-saturated ethylene glycol, giving single exponential decays in 
both cases (Figure S7 in the SI). The lifetime in the presence of dioxygen is considerably shorter ( = 
3.97  0.57 s) compared to degassed solutions ( = 10.65  0.14 s), which is a common phenomenon 
and characteristic for 3MLCT emissions.18, 38 Also in accordance with our tentative assignment of a 
charge-transfer transition is the observation of a strong solvent-dependence of the quantum yields for 
this band (Table 1). 
 
Table 1. Photophysical data for complex [Re(CO)3(L-N3)]Br at room temperature.  
Medium Excitation exc / nm Emission em / nm  Quantum Yields   / % [a] 
Degassed 
Ethylene glycol 317 430, 560 0.14, 0.48 
Degassed 
Ethylene glycol 325 430, 560 0.12, 0.50 
Degassed 
Ethylene glycol 347 430, 560 0.26, 0.51 
Air-saturated 
Water 317 430, 560 0.19, 0.14
 
Air-saturated 
Water 325 430, 560 0.19, 0.14
 
[a] Determined relative to quinine sulfate ( = 54.6%) in 0.5 M sulfuric acid as standard. Estimated 
errors are  30%. 
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Interestingly, the excitation wavelength in degassed ethylene glycol had an effect on the quantum 
yields  of the band at 430 nm ( ranging from 0.12 % to 0.26 %) but not for the “metal-transition” at 
560 nm where remains stable at about 0.50 %. The absolute values for the quantum yields are only 
slightly lower than others previously reported for similar Re compounds.18, 20, 38, 39 
 
Figure 3. Normalized emission spectra of [Re(CO)3(L-N3)]Br in degassed ethylene glycol (black), 
air-saturated ethylene glycol (blue), and in air-saturated water (red) at room temperature (exc = 325 
nm). 
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Figure 4. Excitation spectra for [Re(CO)3(L-N3)]Br in degassed ethylene glycol with emission 
monitored at 430 nm (red) and 560 nm (black). Ratio of luminescence intensities at 560 nm and 430 
nm (dotted). 
 
Taken together, the results of the photophysical measurements, notably the large Stokes shift and the 
long emission lifetimes, make our Re complexes good candidates for fluorescent probes in biological 
experiments (vide infra). 
 
Synthesis and characterization of metal-PNA oligomers. Three different PNA oligomers were 
prepared in this study in order to compare their fluorescence properties as well as the role played by the 
Re complex in the duplex formation (Table 2). In the view of future experiments, all of them are 
complementary to the mRNA expressing the enhanced Green Fluorescent Protein (eGFP) in stably 
transfected eGFP expressing HeLa cells (HeLa-eGFP). Three types of PNA sequences were prepared 
for comparative purposes: a typical “naked” 20-mer PNA sequence complementary to the mRNA 
(abbreviated Naked-PNA) as well as Re-containing and rhodamine-containing PNA sequences, which 
are fully complementary to the mRNA expressing the eGFP (abbreviated Re-PNA and Rho-PNA). The 
rhodamine derivative 5/6-carboxytetramethylrhodamine (present as two regioisomers), has been 
selected on the grounds of its commercial availability and ability to be easily conjugated to PNA 
oligomers.  
 
 
 
 
 
Table 2. Summary of the PNA oligomers used in this study.  
 11
Abbreviatio
n 
Sequence [M + H]+/ [M]+ [a] [M + H]+ or [M]+[b] 
Naked-PNA H-Gly-atgaacttcagggtcagcttgc-Lys-NH2 6180.9 6181.0 
Rho-PNA H-Rho-Gly-atgaacttcagggtcagcttgc-Lys-NH2 6593.3 6594.7 
Re-PNA H-Gly-Re-atgaacttcagggtcagcttgc-Lys-NH2 6998.7 [c] 
[a] Calculated; [b] Experimentally determined by MALDI-TOF (see experimental); [c] Characterized 
by ESI-MS (see Table S1 in the ESI). 
 
All PNA oligomers were synthesized by hand on TentaGel R Fmoc-Lys(Boc)-RAM resin using 
Fmoc/Bhoc-protected PNA monomers and standard protocols, as previously reported by our groups.40 
The C-terminal lysine residue was introduced to enhance solubility.41 A glycine was also inserted at the 
N-terminus of the PNA sequences Naked-PNA and Re-PNA in order to avoid any N-acyl transfer 
reactions.42 For the rhodamine-containing PNA oligomer, the fluorescent label was coupled to the PNA 
sequences following Corey’s method, which involves a “pre-loading” of the resin with the inexpensive 
and unactivated sulforhodamine (see experimental section for further information).43 Naked-PNA and 
Rho-PNA were unambiguously characterized by MALDI-TOF mass spectrometry and their purity 
confirmed by analytical HPLC (see Figures S8-10 in the SI for examples of MALDI-TOF spectra and 
analytical HPLC chromatograms). Various synthetic pathways were previously reported for the 
preparation of metal-containing PNAs.9 In this work, we capitalize on our recent discoveries to 
efficiently attach organometallic complexes to peptides and PNA oligomers using the copper(I)-
catalysed Huisgen 1,3-dipolar cycloaddition reaction, often referred to as “Click Chemistry”.29, 40, 44-48  
In order to label the PNA oligomer with [Re(CO)3(L-N3)]Br, an alkyne-containing PNA monomer44, 46, 
48, 49 (Fmoc-1-OH, Figure 1) was inserted into a PNA sequence before the N-terminal glycine. The 
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azido-containing rhenium tricarbonyl complex [Re(CO)3(L-N3)]Br was then “clicked” to the PNA 
oligomer on the solid phase (see Scheme 2). After cleavage of the oligomers from the resin and 
successive HPLC purification, the Re-containing PNA oligomers, namely Re-PNA, was obtained. Its 
purity was confirmed by analytical HPLC and its identity was ascertained by ESI-MS as well as by IR 
spectroscopy, notably showing the presence of two CO bands in the 1900-2040 cm-1 region (see Table 
S1 and Figures S11–12 in the SI for IR spectra and analytical HPL chromatograms). 
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Scheme 2. Synthesis of Re-containing PNA oligomers. (a) i) CuI, [Re(CO)3(L-N3)]Br, DIPEA, 
DMF; ii) Washing with DMF, CH2Cl2 and DMF; (b) TFA:phenol:TIS 85:10:5 V/V/V. 
Thermal stability studies. In order to determine the influence of the Re complex or the rhodamine 
fluorophore on the stability of DNA/RNA•PNA hybrids, we studied the thermal stability of our PNAs, 
namely Re-PNA, Rho-PNA and Naked-PNA with the 23-mer DNA sequence 5'-
 13
GCAAGCTGACCCTGAAGTTCAT -3'. This DNA sequence was used as a model for the mRNA that 
we will target in future studies. All UV-Vis melting spectra of PNA-DNA can be seen in the SI 
(Figures S13-18). As shown in Table 3, we did not observe any differences between Re-PNA and Rho-
PNA with melting temperatures (Tms) of approximatively 85°C, whilst the Tm of Naked-PNA was 
slightly lower at approximatively 82°C. This indicates that both the Re complex and the rhodamine 
fluorophore actually stabilize the PNA•DNA hybrid, possibly through electrostatic interactions with 
the negatively charged DNA backbone. Any difference observed in the antisense effects between Re-
PNA and Rho-PNA should hence be due to reasons other than PNA•DNA (and PNA•mRNA, 
respectively) hybrid stability. 
 
Table 3. Melting temperatures (Tm / °C) of PNA•DNA hybrids (DNA sequence: 5'-
GCAAGCTGACCCTGAAGTTCAT -3'. 
PNAs Tm / °C 
Naked-PNA 82.2 ± 0.3 
Rho-PNA 85.3 ± 0.1 
Re-PNA 85.3 ± 0.1 
 
Spectroscopic properties of Re-PNA and Re-PNA•DNA. The emission spectra for Re-PNA and its 
Re-PNA•DNA hybrid were recorded at 2 μM strand concentrations in PBS buffer (pH 7.4) after 
excitation at 347 nm. The hybrid formation was induced by heating the equimolar solutions at 90 °C 
for 15 min followed by slowly cooling to room temperature over a period of 2 h. To ensure duplex 
formation, a thermal program from 4°C to 90°C was repeated three times (see experimental section for 
more details). As shown in Figure 5 (dotted line), the emission spectrum for Re-PNA exhibited 
maxima at 397, 432 and 564 nm. Upon hybridisation with the complementary DNA strand (DNA), the 
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position of the maxima and emission intensity for the hybrid Re-PNA•DNA (Figure 5, solid line) 
remained mainly unchanged compared to those of the single strand Re-PNA – viz. the maxima of Re-
PNA•DNA are located at 397, 433 and 574 nm, respectively. This suggests that the photophysical 
properties stay more or less unaffected by the hybridisation process. 
 
Figure 5. Comparison of the emission spectra of Re-PNA (dotted line) and its duplex with the 
complementary DNA (solid line) (2 μM in 0.1 M PBS (pH 7.4) buffer) (exc = 347 nm). 
 
In vitro fluorescence studies. With the Re-containing sequence in hand and having established that 
[Re(CO)3(L-N3)]Br had the required properties for a fluorescent probe, we examined the possibility to 
use the Re complex to localize the PNA bioconjugates within a cell, as previously undertaken by 
Zubieta, Vaillant et al. with other Re-tricarbonyl bioconjugates20, 21, 24, 25, 28 and very recently by 
Licandro et al. with a di-rhenium complex-containing (t)10-PNA decamer.12 HeLa cells were 
transfected with Re-PNA by electroporation and the presence of Re-PNA within the cell was 
unambiguously confirmed by fluorescent microscopy (Figure 6). A minimal concentration of 10 M 
was necessary to allow detection of the Re bioconjugate. The detected fluorescence seemed to 
concentrate in the perinuclear region. Similarly, Rho-PNA was also transfected into HeLa cells and 
likewise, a concentration of 10 M was required to allow good imaging of the cells (see Figure S19 in 
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the SI) suggesting that the Re complex is well-suited for cellular imaging when such concentrations are 
required. PNA are indeed used in the low micromolar range for cellular antisense purposes.50 Of note, 
no intrinsic cytotoxic effects of the Re-PNA and Rho-PNA bioconjugates were visually observed at 
the concentrations up to 25 M. The cells were viable after 48h. These results further support the use 
of organometallic-PNA bioconjugates for in vitro applications. 
 
 
Figure 6. Fluorescence micrographs of HeLa cells 24 h after delivery of three different 
concentrations of Re-PNA by electroporation. Scale bar indicates 50 µm in all images. 
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Conclusion 
In this study, the conjugation of a new fluorescent rhenium tricarbonyl complex, [Re(CO)3(L-
N3)]Br, to a PNA oligomer was successfully carried out using the copper(I)-catalyzed Huisgen azide-
alkyne cycloaddition reaction (Cu-ACC, “click” chemistry) to give Re-PNA. The coupling could be 
successfully performed on the solid phase, underscoring the good stability of the new Re complex. Full 
photophysical characterization confirms the assumed favourable properties of the Re complex, namely 
a large Stokes shift, good quantum yields and long fluorescence lifetime. Importantly, it was 
demonstrated that upon hybridisation with the complementary DNA strand (DNA), the position of the 
maxima and emission intensity for the hybrid Re-PNA•DNA remained mainly unchanged compared to 
those of the single strand Re-PNA. This suggests that the photophysical properties stay more or less 
unaffected by the hybridisation process. These favourable properties translate well into in vitro 
fluorescence microscopy. The new Re-containing PNA oligomer could be indeed detected in living 
cells using fluorescent microscopy at a concentration of 10 M. These findings emphasize that 
organometallic-containing PNAs can indeed be employed for in vitro experiments, contrary to the 
general notion that organometallic compounds are usually unstable under physiological conditions 
and/or cytotoxic. In combination with previously reported techniques of quantitative uptake and 
localization studies of metal bioconjugates in general,10-12 the results reported herein pave the way to 
further development metal-PNA conjugates for biomedical studies. Indeed, preliminary data suggest 
that the metal-PNA conjugates described herein may indeed be used as anti-sense agents. An 18 % 
decrease of expression of the eGFP protein could be observed in genetically modified HeLa cells 48 h 
after incubation with a metal-PNA conjugate targeting the eGFP sequence. Notably, no change in 
protein expression was observed with a conjugate containing a mismatched PNA sequence, suggesting 
a specific antisense effect. While these results are encouraging for the use of metal-PNA conjugates as 
promising multi-functional tools in cell biology, there is certainly scope for optimization and 
experiments along these lines are currently carried out in our laboratories. 
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Experimental Section 
Materials. All reactions were carried out in ordinary glassware and solvents were used without 
further precautions except if indicated. Chemicals were purchased from commercials suppliers and 
used as received. Solvents were used as received or dried over 4 Å molecular sieves. 
Caution! Although no problems were encountered in this work, azide complexes are potentially 
explosive. They should be prepared in small quantities and handled with care. 
Instrumentation and methods. 1H and 13C NMR spectra were recorded in deuterated solvents on a 
Bruker DRX 400 spectrometer at 30°C. The chemical shifts, , are reported in ppm (parts per million). 
The residual solvent peaks have been used as an internal reference. The abbreviations for the peak 
multiplicities are as follows: s (singlet), d (doublet), dd (doublet of doublets), t (triplet), q (quartet), m 
(multiplet) and br (broad). Infrared spectra were recorded on a ATR unit using a Bruker Tensor 27 
FTIR spectrophotometer at 4 cm-1 resolution. Signal intensity is abbreviated br (broad). ESI mass 
spectra were recorded on a Bruker Esquire 6000. All UV-Vis measurements were carried out on a 
VARIAN Cary 100 Conc instrument using quartz cuvettes of 1 cm width. The matrix-assisted laser 
desorption/ionization time of flight mass spectrometry (MALDI-ToF) mass spectra were measured on a 
Bruker Daltonics Autoflex. The experiments were performed in linear mode with positive polarity 
using sinapinic acid as the matrix. HPLC purification was performed on an Agilent Series 1100 system 
equipped with a C18 Nucleodur gravity column (125 x 21 mm, 5 µm particle size, Macherey-Nagel). 
Preparative (flowrate: 10.0 mL min-1) runs were performed with a linear gradient of A (millipore® 
water containing 0.1 % v/v TFA) and B (acetonitrile (Baker HPLC-grade), containing 0.1 % v/v TFA): 
t = 0 min 5 % B. t = 35 min 52 % B. t = 45 min 100 % B. t = 55 min 100 % B. t = 60 min 0 % B. LC-
MS experiments were performed on an Agilent 1100 series HPLC system connected to a Thermo LCQ 
Advantage mass spectrometer equipped with an electrospray ion source. A C18 Nucleodur gravity 
column (125 x 4 mm, 3 µm particle size, Macherey-Nagel) was used for small molecules. Material was 
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eluted using a gradient system of acetonitrile (B) and water containing 0.1% formic acid (A) and a flow 
rate of 1 mL min-1. t = 0-1 min (10 % B), t = 1-10 min (from 10 to 100 % B), t = 10-12 min (100 % B). 
Synthesis and Characterization. 
2-(bis((quinolin-2-yl)methyl)amino)ethanol (L-OH). L-OH was prepared following the procedure 
published by Zubieta et al.31 
2-(N-(2-(((9H-fluoren-9-yl)methoxy)carbonylamino)ethyl)pent-4-ynamido)acetic acid (Fmoc-1-
OH). Fmoc-1-OH was prepared following the procedure published by Gasser et al.44 The 
spectroscopic data of the products matched that reported previously.44 
[NEt4][ReBr3(CO)3]. [NEt4][ReBr3(CO)3] was prepared following the procedure published by 
Alberto et al. The spectroscopic data of the products matched that reported previously.33 
2-azido-N,N-bis((quinolin-2-yl)methyl)ethanamine (L-N3). To a solution of 2-(bis((quinolin-2-
yl)methyl)amino)ethanol (1.00 g, 2.91 mmol) and triphenylphosphine (1.54 g, 5.82 mmol) in dry THF 
(40 mL) was slowly added diisopropyl azodicarboxylate (1.218 mL, 5.82 mmol) under a nitrogen 
atmosphere. The mixture was stirred for 5 min before diphenylphosphoryl azide (1.294 mL, 5.82 
mmol) was slowly added to the solution. The reaction mixture turned from brown to dark brown with 
the appearance of a white precipitate. The mixture was stirred for 72h at room temperature, time during 
the precipitate disappeared. The solvent of the reaction mixture was then evaporated to dryness to give 
a brown oil. In order to remove the major impurities of the product (excess reagents), this oil was 
dissolved in CH2Cl2 (100 mL) and the compound was transferred into the aqueous phase with 1M 
HCl(aq) (3x75 mL) (the majority of the reagents stay in the organic phase). The combined aqueous 
phases were rendered basic (pH = 13) with 5M NaOH(aq) and extracted with CH2Cl2 (3x100 mL). The 
combined organic phases were then concentrated under vacuo to give a brown oil. A purification by 
column chromatography on neutral alumina was then performed using CH2Cl2:MeOH 100:0.5 as the 
eluent to give a slightly yellow solid (Rf = 0.25). Yield. 0.34 g (32 %). Characterization Data. 
Analyses Found (%): C, 71.82; H, 5.00; N, 22.56. Calcd for C14H16N6 (%): C, 71.72; H, 5.47; N, 22.81. 
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IR bands (, cm-1): 3057 w, 2967 w, 2929 w, 2841 w, 2185 w, 2093 s, 1971w, 1715 w, 1666 w, 1600 
m, 1563 w, 1500 m, 1451 w, 1424 m, 1361 w, 1295 br m, 1116 w, 1036 w, 1007 w, 965 m, 944 w, 882 
w, 829 s, 796 m, 764 m, 644 w, 617 w. 1H NMR Spectrum (CDCl3):  2.92 (t, 3J = 5.9 Hz, 2H, N-CH2-
CH2), 3.34 (t, 3J = 5.9 Hz, 2H, CH2-CH2N3), 4.08 (s, 4H, N-CH2-quin), 7.49 (m, 2H, CH quin), 7.64-
7.80 (m, 6H, CH quin), 8.03 (m, 2H, CH quin), 8.14 (m, 2H, CH quin). 13C NMR Spectrum (CDCl3):  
49.4 (CH2-CH2N3), 54.0 (N-CH2-CH2), 61.9 (N-CH2-pyr), 121.3 (CH), 126.5 (CH), 127.7 (C), 127.8 
(CH), 129.3 (CH), 129.7 (CH), 136.7 (CH), 147.8 (C), 160.0 (C, all from the quinoline ligands). 
Electrospray Mass Spectrum (m/z): 369.1 [M+H]+ (100%), 391.1 [M+Na]+ (63%). High-Resolution 
Mass Spectrum (EI): calcd. for C22H20N6 ([M]+): 368.1749; found: 368.1749. 
Rhenium tricarbonyl complex of L-N3 ([Re(CO)3(L-N3)]Br). 2-azido-N,N-bis((quinolin-2-
yl)methyl)ethanamine (50 mg, 0.14 mmol) and [NEt4]2[ReBr3(CO)3] (105 mg, 0.14 mmol) were 
refluxed in deoxygenated methanol (20 mL) for 3h. The reaction mixture, which turned yellow-brown, 
was evaporated to dryness. A purification by column chromatography on silica with a gradient of 
CH2Cl2:MeOH 100:7 to CH2Cl2:MeOH 10:1 as the eluent (Rf = 0.38 in CH2Cl2:MeOH 10:1) was 
performed to give a slightly yellow solid. Crystals suitable for X-ray crystallography were grown by 
letting slowly evaporated a solution of ([Re(CO)3(L-N3)]Br in CD3OD over 3 days. Yield. 80 mg (84 
%). Characterization Data. Major IR bands (, cm-1): 3389 br w, 3057 w, 2925 w, 2101 m, 2025 s, 
1897 s, 1715 w, 1601 w, 1568 w, 1514 w, 1464 w, 1434 w, 1370 w, 1343 w, 1290 w, 1259 w, 1209 w, 
1145 w, 1125 w, 1086 w, 1028 w, 972 w, 916 w, 871 w, 825 w, 781 w, 749 w, 646 w.1H NMR 
Spectrum (CD3OD, just after dissolution):  4.13 (s, br, 4H, N-CH2-CH2 and CH2-CH2N3), 5.21 (d, 2J = 
17.7 Hz, 2H, N-CH2-quin), 5.30 (d, 2J = 17.7 Hz, 2H, N-CH2-quin), 7.69 (m, 4H, CH quin), 7.86 (m, 
2H, CH quin), 8.01 (m, 2H, CH quin), 8.52 (m, 4H, CH quin). 13C NMR Spectrum (CD3OD, long after 
dissolution):  49.6 (CH2-CH2N3) (under the MeOD peak), 67.1 (N-CH2-CH2), 68.0 (m, N-CH2-pyr), 
121.1 (CH quin), 129.6 (CH quin), 129.6 (CH quin), 130.0 (C quin), 131.0 (CH quin), 134.2 (CH quin), 
143.1 (CH quin), 148.3 (C quin), 166.3 (C quin), 195.4, 197.1 (fac-Re(CO)3). Electrospray Mass 
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Spectrum (m/z): 639.0 [M]+ (100%). High-Resolution Mass Spectrum (EI): calcd. for C25H20N6O3Re 
([M]+): 639.1154; found: 639.1192. 
Peptide nucleic acid synthesis. The PNAs were prepared by solid-phase peptide synthesis (SPPS). 
SPPS was performed manually in 5 mL polypropylene one-way syringes as reaction vessels, which 
were equipped with a frit at the bottom. They were filled with 125 mg of polystyrene resin beads 
TentaGel R RAM Lys(Boc)Fmoc (0.18 mmol/g) from Rapp Polymere. The resin was swollen in DMF 
before use for 1 h. All reactions were performed on a mechanical shaker at 400 rpm, soaking 
approximately 3-4 mL of freshly prepared solutions into the syringe. Fmoc/Bhoc protected PNA 
monomers or the Fmoc-spacer (5 eq) (all from Link Technologies, Lanarkshire, Scotland) were 
preactivated in Eppendorf tubes before every coupling step for 2 min with HATU (4.5 eq) in DMF, 
adding DIPEA and 2,6-lutidine (10 eq each) (A(bhoc)-PNA-monomer: 5 min, C(bhoc)-PNA-monomer: 
7 min). For each coupling step the resin beads were treated with the activated acid under vibration and 
subsequently washed with DMF. The coupling step was monitored with the Kaiser test. Double Fmoc 
deprotection was performed with piperidine (20 %, v/v) in DMF (2 min + 10 min). The resin beads 
were then washed successively with DMF, DCM and DMF. The whole procedure (deprotection, 
coupling, monitoring) was repeated for every PNA monomer until the PNA sequence was completed. 
The insertion of the synthon Fmoc-1-OH into the PNA oligomers was performed according to the 
general SPPS procedure. Before cleavage, the resin was shrunk with methanol and dried. The non-
rhenium containing PNAs were then cleaved using a mixture of trifluoroacetic 
acid:water:triisopropylsilane 95:2.5:2.5 v/v/v while the rhenium containing PNAs were cleaved using a 
mixture of TFA:phenol:TIS 85:10:5 V/V/V [3 x 400 l (1h30 each)]. The resulting solutions were first 
evaporated to dryness before being precipitated with ice-cold ether. The solids were centrifuged, 
washed with ice-cold ether and finally air dried. The obtained crude oligomers were lyophilized in 
acetonitrile / water, purified and analyzed with RP-HPLC and finally characterized with ESI or 
MALDI-TOF mass spectrometry. 
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General procedure for the synthesis of Rhodamine-containing PNA oligomers. These oligomers 
were prepared using a similar method to this one developed by Corey et al.43 The PNA sequence to be 
labelled containing resin (2 mol) was introduced into a fritted syringe and was subsequently swollen 
with DMF for 1h. Sulforhodamine (15.7 mg) dissolved in a mixture DIPEA:DMF 1:30 v/v (500 L) 
was introduced into the syringe and the mixture was shaken for 30 min., at r.t., in the dark. The resin 
was then thoroughly washed with a mixture of DMF:CH2Cl2 v/v to remove unbound sulforhodamine. 
The N-terminal Fmoc protecting group of the PNA sequence was then removed using a mixture 
Piperidine 20% in DMF (2 x 10 min). The resin was again washed with DMF. 5-(and -6)-
carboxytetramethylrhodamine succinimidyl ester (supplied as a mixture of isomers) (6 mg) dissolved in 
a mixture of DIPEA:DMF 1:30 v/v (500 L) was introduced to the syringe and the mixture was shaken 
for 21h, at r.t., in the dark. The resin was then washed thoroughly with DMF. See above for the details 
of the subsequent cleavage of the resin. 
General procedure for the synthesis of Rhenium-containing PNA oligomers by Click 
Chemistry. The synthon 1 containing PNA resin was shrunk with methanol, dried over vacuum and 
then transferred into a fritted syringe. The resin was then swollen with DMF for 1h. The N-terminal 
Fmoc protecting group of the PNA sequence was then removed using a mixture of piperidine 20% in 
DMF (2 x 10 min). The resin was again washed with DMF. [Re(CO)3(L-N3)]Br (3.0 eq.) and CuI (2.5 
eq.) were then introduced into the syringe (from the top). Afterwards, a mixture of 
ethyldiisopropylamine (54 L) and DMF (400 L) were aspired up the syringe and the mixture was 
shaken for 3 days at room temperature in the absence of light and under an argon atmosphere. The resin 
was then washed with DMF (5x), CH2Cl2 (5x) and DMF (5x) successively. See above for the details of 
the subsequent cleavage of the resin. 
Calculation of the Extinction Coefficient of Re(CO)3(L-N3)]Br. The extinction coefficient of the 
rhenium complex in the PNA oligomer was estimated using Re(CO)3(L-N3)]Br as model compound. 
The absorption of Re(CO)3(L-N3)]Br in H2O at 80°C at 260 nm was measured in the concentration 
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range of 20 – 50 µM with increments of 10 µM. The gradient of the linear plot of the absorption 
against the concentration allows for the calculation of the extinction coefficient, 260 = 9040 M-1cm-1. 
PNA Concentration Determination. PNA concentration was measured by means of the absorption 
at 260 nm using the incremental extinction coefficients of the PNA  (PNA,A = 13700 M-1cm-
1, PNA,G = 11700 M-1cm-1, PNA,C = 6600 M-1cm-1, PNA,T = 8600 M-1cm-1) for the Re-containing PNA 
oligomers2 and at 555 nm for the rhodamine-containing PNA oligomers using 65000 cm-1 as the 
extinction coefficient. The different PNAs were dissolved in MQ water and then filtered to produce 
stock solutions. Small aliquots of these stock solutions were then highly diluted in Phosphate Buffer 
(100 mM, pH = 7.4). The measurements were carried out at 80°C where the PNA strands are 
completely destacked for the naked and Re-containing PNA oligomers and at 20°C for rhodamine-
containing PNA oligomers.  
Thermal stability studies. Solutions of PNA and DNA oligomers were all brought to 3 M in 
phosphate buffer, pH = 7.4. The duplexes were annealed at 90°C for 15 min and then cooled down 
slowly to room temperature in the spectrometer. Thermal program: starting and returning temperature 
was 25°C. Heating to 90°C, cooling to 4°C, each at 0.5°C/min and holding for 3 min at the end-
temperatures. The procedure was repeated three times. 
Re-PNA and Re-PNA•DNA sample preparation for fluorescence measurements. Fluorescence 
measurements were performed with solutions of 2 µM Re-PNA and of 2 µM of the hybrid Re-
PNA•DNA, each in 0.1 M PBS buffer, pH = 7.4. The preparation of the hybrid Re-PNA•DNA is 
similar to those of the thermal stability studies. Shortly, the hybrid formation was induced by heating 
the equimolar solutions of Re-PNA and DNA at 90 °C for 15 min and then cooled down slowly to 
room temperature in the spectrometer. To ensure duplex formation the thermal program was done 
subsequently: starting and returning temperature was 25°C. Heating to 90°C, cooling to 4°C, each at 
0.5°C/min and holding for 3 min at the end-temperatures. The procedure was repeated three times. 
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Fluorescence measurements. Steady state emission spectra were acquired on a PTI Quantamaster 
QM4 spectrofluorimeter51 using 1.0 cm quartz cuvettes. The excitation light source was a 75 W 
continuous xenon short arc lamp. Emission and excitation spectra were collected at 90° to the 
excitation beam using a PTI R928 photomultiplier tube (operated at -1000 V) as the detector. Spectral 
selection was achieved by single grating monochromators (1200 grooves/mm, blazed at 300 nm for the 
excitation and at 400 nm for the emission). Quantum yields were measured with optically dilute 
solutions (A < 0.1) using the following equation: 
 
where A is the absorbance at the excitation wavelength (), I is the intensity of the excitation light at 
the same wavelength,  is the refractive index and D is the integrated luminescence intensity of the 
respective emission peak. The integrals of the two emission peaks at ca. 430 nm and ca. 560 nm were 
deconvoluted by a fitting procedure with two overlapping Voigt functions using Origin Pro 8G.52  The 
subscripts ‘x’ and ‘r’ refer to the sample and reference respectively. Quantum yields were determined 
relative to quinine sulfate hemihydrate (in 0.5 M sulfuric acid, r = 0.546) as standard.53 The estimated 
errors for the obtained values are  30%. 
Luminescence lifetimes were measured with the same PTI Quantamaster QM4 spectrofluorimeter 
equipped with an additional Q4 phosphorescence module. The light source for these measurements was 
a xenon flash lamp (Hamamatsu L4633: 100 Hz repetition rate, pulse width ca. 1.5 s FWHM). 
Emission was measured at 90° using a PTI P1.7R detector module (Hamamatsu PMT R5509-72 with a 
Hamamatsu C9525 power supply operated at -1500 V and a Hamamatsu liquid N2 cooling unit C9940 
operated at -80°C). Spectral selection of the emission was achieved by passage through a single grating 
emission monochromator (1200 grooves/mm, blazed at 400 nm). The instrument response function was 
determined using a dilute aqueous solution of colloidal silica (Ludox® AM-30). Lifetime data analysis 
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(deconvolution, statistical parameters, etc.) was performed using the software package FeliX32 from 
PTI.51 The given values are averages of three independent measurements. Estimated error values for 
the obtained lifetimes are  20%. 
Cell Culture. Experiments were performed on human cervix epithelial cells (HeLa). The cells were 
cultured in CCM (cell culture medium: Dulbecco’s modified Eagle’s medium (DMEM) supplemented 
with 10% fetal calf serum (FCS), 2 mM glutamine, 100 U mL-1 penicillin, 100 µg mL-1 streptomycin) 
in T 75 flasks (Sarstedt, Nümbrecht, Germany) at 37°C and 10% CO2. All media and reagents were 
purchased from PAA, Cölbe, Germany. The cells were split by tripsination (2.5 mg/ml Trypsin with 
0.02M EDTA) and subcultivated every 4-7 days. 
Cell Transfection – Electroporation (fluorescent microscope measurements). PNA was delivered 
by electroporation using the Amaxa Cell Line Nucleofactor® Kit R (Lonza Cologne AG, Köln, 
Germany) according to the manufactures’ manual. In short after cell harvesting a cell pellet of 1 x 106 
cells was resuspended in 100 µL Nucleofector® Solution and supplemented with 1, 10 or 20 µM of 
PNA. Nucleofection® was carried out using the Nucleofector® Program I-13. Afterwards the cells were 
transferred into an excess of pre-equilibrated CCM and shortly centrifuged at 80xg. Finally 5 x 105 
cells per well were cultivated in 24 well plates (TPP, Trasadingen, Switzerland) at 37°C and 10% CO2. 
As a control, cells were electroporated without delivering any target. 
In vitro Fluorescence Evaluation. The cellular localization of the fluorescent PNA bioconjugates 
was confirmed by fluorescence microscopy. Different concentrations (1, 10 and 20 µM) of Re-PNA or 
Rho-PNA respectively were electroporated into HeLa cells as described above. One day after delivery 
the CCM was removed by phosphate buffered saline (PBS) and microscopic pictures were taken from 
live cells. The Re bioconjugate was excited between 330 - 385 nm and the fluorescence was detected at 
>420 nm on an Olympus IX 81 motorized inverted microscope (Olympus, Hamburg, Germany). The 
Rho complex was excited by a HeNe laser at 543 nm and the fluorescence was detected in the range of 
548 nm to 698 nm on a Zeiss Axioplan LSM 510 meta microscope. 
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X-ray Crystallography. Crystallographic data for Re(CO)3(L-N3)]Br have been deposited with the 
Cambridge Crystallographic Data Centre as supplementary publication (CCDC no. 757065). Copy of 
the data can be obtained, free of charge, on application to CCDC, 12 Union Road, Cambridge CB2 
1EZ, UK, (fax: +44-(0)1223-336033 or e-mail: deposit@ccdc.cam.ac.uk or via 
www.ccdc.cam.ac.uk/data_request/cif). Crystallographic data for Re(CO)3(L-N3)]Br. 
C52H46Br2N12O8Re2, M = 1499.23, triclinic, space group P-1, a = 9.707(5), b = 10.899(5), c = 
12.796(6) Å,  = 74.586(9),  = 85.97(1),  = 86.817(9)o, V = 1300.9(11) Å3, Z = 1, 2max = 50.23o, 
7168 measured reflections, 4498 independent reflections, 338 parameters,  = 6.251 mm -1, R1 = 
0.0632 for 4358 observed reflections (I > 2(I)), wR2 = 0.1641for all reflections. Bruker-axs-SMART 
1000 CCD. Structure solution with direct methods (SHELXS97), and refined against F2 with all 
measured reflections (SHELXL9718 Platon/Squeeze19). 
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